1,721,058 research outputs found
Detection of antibody to HIV env glycoprotein in blood donors with indeterminate results on Western blotting
No full textThe ability of Procleix Ultrio assay to detect HBV DNA in HBsAg positive blood donors
No full textIn the past decade, a new form of therapy based on biological rather than pharmacological intervention has been developed. The term 'cell therapy', as applied to this new therapeutic tool, means the administration of living, non-germline somatic cells to humans for diagnostic or therapeutic purposes. Cell therapy products (CTPs) are generated by ex vivo processes, which comprise cell harvesting from patients or healthy donors, in vitro manipulation and administration of the manipulated cells to patients. The aim of ex vivo processes is to obtain cell subsets with defined functional properties that are capable of replacing or repairing damaged tissues or organs. Some examples of cell therapy are transplantation of expanded haematopoietic stem cells (HSCs), adoptive immunotherapy and dendritic cell vaccination to augment or restore the immune response for the treatment of malignant or infectious diseases. The types of cells most frequently used for cell therapy include haematopoietic pluripotent progenitor and stem cells from the bone marrow and peripheral blood, T-cell clones and dendritic cells. Although CTPs should be produced according to good manufacturing practice, they differ from traditional pharmaceutical products with regard to quality control and safety aspects. These differences prompted the development of a number of documents issued by regulatory bodies, which specifically address CTPs. This review discusses several issues related to the design, construction and validation of a hospital-based facility for the production of CTPs, the implementation of cell-manipulation processes and quality control of the final products
Prevalenza dell'infezione da GB virus-C/HGV in un gruppo di pazienti HIV e HCV-RNA positivi
No full text
Profilassi con Interferone e ribavirina in pazienti HCV-RNA postivi sottoposti a trapianto di fegato: una nuova strategia contro la recidiva di epatite C
No full textEpidemiology of tetanus
No full textThe vaccinal preventive measures which were made compulsory since 1963 for the new working levies of some professional high risk categories, and since 1968 for the newborns, contributed to a large extent to the tetanus control in our country. In the last twenty years a progressive drop in the notified tetanus cases was observed. The epidemiology of this disease is conditioned, on the one hand by the correct application of the legal directions in force; on the other hand, by the level of health education, acquired by those who have not yet been involved, so far, by the compulsory antitetanus vaccination
Hepatitis C virus antibody response in acute and chronic non-A, non-B hepatitis.
No full textPatients with post-transfusion, community-acquired or hemodialysis-acquired non-A, non-B hepatitis (NANBH) were tested for antibody to hepatitis C virus (HCV) during acute-phase and resolving or chronicized illness. HCV appears to be involved in most cases of post-transfusion and hemodialysis-acquired NANBH, but only in 40% of community-acquired NANBH. Second generation HCV antibody assays are more specific and sensitive, favoring early detection of HCV seroconversion and identification of HCV-antibody-positive individuals years after exposure to the virus
Hepatitis B virus S-gene mutants in HBsAg positive blood donors and in patients with hepatocellular carcinoma and controls with overt or occult HBV infection
No full text
- …
